E-LIB Suche - Ergebnisse für: Bygrave, C.J

1

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAF..:

Khwaja, J ; Bomsztyk, J ; Mahmood, S...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431027/. , 2022

Link: http://www.ncbi.nlm.nih...

2

Risk and response adapted therapy following autologous stem..:

Royle, KL ; Coulson, AB ; Ramasamy, K...
https://discovery.ucl.ac.uk/id/eprint/10161450/1/e063037.full.pdf. , 2022

Link: https://discovery.ucl.ac..

3

Risk and response adapted therapy following autologous stem..:

Royle, K-L ; Coulson, AB ; Ramasamy, K...
https://eprints.whiterose.ac.uk/194115/11/e063037.full.pdf. , 2022

Link: https://eprints.whiteros..

4

Efficacy of Isatuximab With Pomalidomide and Dexamethasone ..:

Djebbari, F ; Rampotas, A ; Vallance, G...
https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35651713/. , 2022

Link: https://doi.org/10.1097/..

5

Efficacy of Isatuximab with Pomalidomide and Dexamethasone ..:

Djebbari, F ; Rampotas, A ; Vallance, G...
https://discovery.ucl.ac.uk/id/eprint/10171714/1/IsaPomDex%20HemaSphere.pdf. , 2022

Link: https://discovery.ucl.ac..

6

Carfilzomib or bortezomib in combination with cyclophospham..:

Yong, KL ; Hinsley, S ; Auner, HW...
Haematologica: the hematology journal, 2021, 106 (10), pp. 2694 - 2706. , 2022

Link: https://repository.icr.a..

7

Infections in relapsed myeloma patients treated with isatux..:

Djebbari, F ; Rampotas, A ; Vallance, G...
https://www.tandfonline.com/doi/full/10.1080/16078454.2022.2082725. , 2022

Link: https://doi.org/10.1080/..

8

Thrombotic microangiopathy in untreated myeloma patients re..:

Camilleri, M ; Cuadrado, M ; Phillips, E...
https://discovery.ucl.ac.uk/id/eprint/10123458/1/bjh.17377.pdf. , 2021

Link: https://discovery.ucl.ac..

9

Carfilzomib or bortezomib in combination with cyclophospham..:

Yong, KL ; Hinsley, S ; Auner, HW...
Haematologica: the hematology journal. , 2021

Link: http://hdl.handle.net/10..

10

Early relapse after high‐dose melphalan autologous stem cel..:

Bygrave, C ; Pawlyn, C ; Davies, F...
https://eprints.whiterose.ac.uk/161799/7/Br%20J%20Haematol%20-%202020%20-%20Bygrave%20-%20Early%20relapse%20after%20high%E2%80%90dose%20melphalan%20autologous%20stem%20cell%20transplant%20predicts%20inferior.pdf. , 2021

Link: https://eprints.whiteros..

11

COVID-19 and myeloma clinical research - experience from th..:

Camilleri, M ; Sive, J ; Wilson, W...
https://discovery.ucl.ac.uk/id/eprint/10122629/3/Yong_CARDAMON%20and%20COVID19%2018.8.20%20Final%20for%20Approval_BP.ky-1.pdf. , 2021

Link: https://discovery.ucl.ac..

12

Carfilzomib or bortezomib in combination with cyclophospham..:

Yong, KL ; Hinsley, S ; Auner, HW...
https://discovery.ucl.ac.uk/id/eprint/10127272/1/10255-Article%20Text-75341-1-10-20210429.pdf. , 2021

Link: https://discovery.ucl.ac..

13

Real-world assessment of the clinical impact of symptomatic..:

Cook, G ; John Ashcroft, A ; Pratt, G...
British journal of haematology, 2020, 190 (2), pp. e83 - e86. , 2020

Link: https://repository.icr.a..

14

Early relapse after high-dose melphalan autologous stem cel..:

Bygrave, C ; Pawlyn, C ; Davies, F...
British journal of haematology, 2020. , 2020

Link: https://repository.icr.a..

15

P918: HIGH RESPONSES RATES WITH SINGLE AGENT BELANTAMAB MAF..:

J. Khwaja ; J. Bomsztyk ; S. Mahmood...
http://journals.lww.com/10.1097/01.HS9.0000846540.61863.d3. , 2022

Link: https://doi.org/10.1097/..